Kintor Pharmaceutical Ltd is an investment holding company primarily engaged in the research and development of innovative medicine products. The Company's products are dedicated to addressing disease areas that have not met clinical needs, and its pipeline mainly covers indications of dermatology (such as androgenetic alopecia, acne vulgaris) and indications of tumors. The Company has two core drugs in the dermatology field, KX-826 and GT20029. The Company's other disease areas include metastatic castration-resistant prostate cancer (mCRPC), liver cancer, idiopathic pulmonary fibrosis, malignant blood diseases and various solid tumors.

Employees

123

Sector

Biotechnology & Medical Research

More about the company

Annual profits - Rate of surprise

Company calendar

Market Closed - OTC Markets 10:46:29 2026-08-12 am EDT			5-day change	1st Jan Change
0.2399 ^USD	+39.48%		0.00%	+11.06%

Aug. 19	Kintor Pharmaceutical Limited Reports Earnings Results for the Half Year Ended June 30, 2026	CI
Jun. 10	Kintor Pharma Posts Positive Interim Safety Data for Whitening Agent KT-939	MT

Market Cap	716M 106M 91.38M 85.76M 78.33M 148M 10.15B 149M 1.01B 393M 5.12B 400M 391M 16.97B	P/E 2024	-2.53x	P/E 2025	-3.96x
Enterprise Value	770M 114M 98.25M 92.22M 84.23M 159M 10.92B 160M 1.09B 423M 5.51B 430M 420M 18.24B	EV / Sales 2024	75,794,130x	EV / Sales 2025	28,245,180x
Free-Float	88.01%	Yield 2024 *	-	Yield 2025	-

Aug. 19	Kintor Pharmaceutical Limited Reports Earnings Results for the Half Year Ended June 30, 2026	CI
Jun. 10	Kintor Pharma Posts Positive Interim Safety Data for Whitening Agent KT-939	MT
Jun. 10	Kintor Pharmaceutical Limited Announces Positive Interim Result in Long-Term Human Safety Trial of Kt-939 and Commences Registration Application for New Raw Material	CI
May. 28	Kintor pharmaceutical says CEO via wholly owned co increases shareholding by 2.51 million shares	RE
May. 27	Kintor Pharmaceutical Auditor to Retire; Shares Drop 7%	MT
May. 26	Kintor Pharmaceutical Limited Announces Change of Address of Principal Place of Business in Hong Kong, with Effect from 1 June 2026	CI
Apr. 21	Kintor Pharmaceutical's 2026 Sales Jump Past 2025 Full-Year Level	MT
Apr. 20	Kintor Pharmaceutical says ytd 2026 sales revenue at RMB34 million	RE
Apr. 20	Kintor Pharmaceutical Limited Provides Sales Guidance for the Year 2026	CI
Apr. 20	Kintor Pharmaceutical Limited Announces Preliminary Sales Results for the Year to Date Ended April 20, 2026	CI
Mar. 30	Kintor Pharmaceutical Limited Reports Earnings Results for the Full Year Ended December 31, 2025	CI
Mar. 19	Kintor Pharma's Androgenetic Alopecia Drug Meets Primary Endpoint in Phase 3 Trial; Shares Plunge 21%	MT
Mar. 18	Kintor pharmaceutical says pharma's KX-826 phase III trial in China reaches primary endpoint	RE

23-10-27	Kintor Pharmaceutical : Pharma Announces Publication of Phase Ib/II Data from GT90001 and Nivolumab Combination Therapy for Advanced HCC in BMC Medicine	PU
23-10-11	Kintor Pharmaceutical : Pharma Announces the Approval of Phase II Clinical Trial of Hedgehog/SMO Inhibitor GT1708F for Treatment of IPF in China	PU
23-08-28	Kintor Pharmaceutical : Pharma Announces 2023 Interim Results and Recent Business Highlights	PU
23-08-22	Kintor Pharmaceutical : Pharma Announces Completion of Patient Enrollment in Phase II Clinical Trial of GT20029 for Treatment of Androgenetic Alopecia in China	PU
23-07-20	Kintor Pharma Announces Completion of First Patient Enrollment in KX-826 Long-term Safety Phase III Trial for Treatment of AGA	AQ

Kintor Pharmaceutical Limited Stock OTC Markets

Stocks

KNTPF

KYG5273B1077

Biotechnology & Medical Research

Valuation : Kintor Pharmaceutical Limited

Chart: Kintor Pharmaceutical Limited

Latest news : Kintor Pharmaceutical Limited

Press Releases : Kintor Pharmaceutical Limited

Quotes and Performance

Price Extremes

Managers and Directors : Kintor Pharmaceutical Limited

Bio Therapeutic Drugs

Financials

Company Profile

Annual profits - Rate of surprise

1 day	+39.48%
Current month	+39.48%
1 month	+4.30%
3 months	-25.48%
6 months	-38.85%
Current year	+11.06%

1 month	0.17	0.24
Current year	0.17	0.57
1 year	0.17	0.57
3 years	0.08	0.57
5 years	0.08	11.8
10 years	0.08	11.8

Manager	Title	Age	Since
You Zhi Tong CEO	Chief Executive Officer	64	2009-03-23
Ming Ming Cheung DFI	Director of Finance/CFO	49	2023-04-13
Hong Long Lu CTO	Chief Tech/Sci/R&D Officer	49	2020-08-31

Director	Title	Age	Since
Yeung Wai Yim BRD	Director/Board Member	62	2019-08-11
Min Xu BRD	Director/Board Member	61	2019-08-11
You Zhi Tong CHM	Chairman	64	2009-03-23

Add to a list 0 selected To use this feature you must be a member Log in Sign up	Change	5-day change	1-year change	3-year change	Capi.($)
KINTOR PHARMACEUTICAL LIMITED	+39.48%	0.00%	-	-	106M
WUXI APPTEC CO., LTD.	+3.31%	-3.70%	+61.03%	+103.64%	70.42B
ARGENX SE	+0.74%	+2.12%	+48.78%	+92.50%	65.4B
BIONTECH SE	-1.31%	-0.50%	+7.41%	-4.29%	28.28B
WUXI BIOLOGICS (CAYMAN) INC.	-0.49%	+1.73%	+59.01%	+11.60%	26.57B
INSMED INCORPORATED	+0.40%	-4.80%	-5.89%	+469.55%	27.16B
GENMAB A/S	+0.14%	+0.89%	+36.11%	-17.87%	20.09B
PHARMAESSENTIA CORPORATION	+1.02%	+6.43%	+269.42%	+420.34%	20.61B
SICHUAN KELUN-BIOTECH BIOPHARMACEUTICAL CO., LTD.	+0.77%	-1.59%	+13.19%	+543.56%	15.87B
EXELIXIS, INC.	-1.09%	+3.14%	+46.32%	+155.12%	13.9B
Average	+4.29%	+1.16%	+59.49%	+197.13%	32.03B
Weighted average by Cap.	+0.92%	+0.72%	+56.32%	+157.40%

	2024	2025
Net sales	5 0.74 0.64 0.6 0.55 1.03 70.93 1.04 7.09 2.75 35.78 2.79 2.73 118.52	32.68 4.86 4.17 3.92 3.58 6.75 463.62 6.78 46.34 17.96 233.89 18.25 17.85 774.68
Net income	-155M -23.1M -19.82M -18.61M -16.99M -32.07M -2.2B -32.23M -220M -85.34M -1.11B -86.72M -84.84M -3.68B	-200M -29.76M -25.55M -23.98M -21.9M -41.33M -2.84B -41.53M -284M -110M -1.43B -112M -109M -4.74B
Net Debt	-15.68M -2.33M -2M -1.88M -1.72M -3.24M -222M -3.25M -22.23M -8.62M -112M -8.76M -8.57M -372M	53.86M 8.01M 6.88M 6.45M 5.89M 11.12M 764M 11.18M 76.37M 29.6M 385M 30.08M 29.43M 1.28B